Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Getting to Long-Term Effectiveness and Safety of Attention-deficit Hyperactivity Disorder Medications.

Beau-Lejdstrom R, Zito JM.

Clin Pharmacol Ther. 2018 Oct;104(4):610-612. doi: 10.1002/cpt.1137. Epub 2018 Aug 17.

PMID:
30120774
2.

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.

Storebø OJ, Faltinsen E, Zwi M, Simonsen E, Gluud C.

Clin Pharmacol Ther. 2018 Oct;104(4):606-609. doi: 10.1002/cpt.1149. Epub 2018 Jul 13.

PMID:
30006934
3.

Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Froehlich TE, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E.

Clin Pharmacol Ther. 2018 Oct;104(4):619-637. doi: 10.1002/cpt.1192. Epub 2018 Aug 30.

PMID:
30053315
4.

Treating a Child With Mental Illness.

Ito S.

Clin Pharmacol Ther. 2018 Oct;104(4):592-594. doi: 10.1002/cpt.1182.

PMID:
30222188
5.

Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.

Myhre O, Låg M, Villanger GD, Oftedal B, Øvrevik J, Holme JA, Aase H, Paulsen RE, Bal-Price A, Dirven H.

Toxicol Appl Pharmacol. 2018 Sep 1;354:196-214. doi: 10.1016/j.taap.2018.03.015. Epub 2018 Mar 14. Review.

PMID:
29550511
6.

MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.

Schweren LJ, de Zeeuw P, Durston S.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64. doi: 10.1016/j.euroneuro.2012.10.014. Epub 2012 Nov 17. Review.

PMID:
23165220
7.
8.

The use of melatonin in Swedish children and adolescents--a register-based study according to age, gender, and medication of ADHD.

Furster C, Hallerbäck MU.

Eur J Clin Pharmacol. 2015 Jul;71(7):877-81. doi: 10.1007/s00228-015-1866-3. Epub 2015 May 22.

PMID:
25995170
9.

Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.

Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK.

Lancet Psychiatry. 2018 Oct;5(10):824-835. doi: 10.1016/S2215-0366(18)30293-1. Epub 2018 Sep 13.

PMID:
30220514
10.

Medications used in the treatment of disruptive behavior in children with FASD--a guide.

Ozsarfati J, Koren G.

J Popul Ther Clin Pharmacol. 2015;22(1):e59-67. Epub 2015 Feb 12. Review.

PMID:
25715382
11.

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.

12.
14.

The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI.

Eur J Clin Pharmacol. 2013 Mar;69(3):589-98. doi: 10.1007/s00228-012-1344-0. Epub 2012 Jul 19.

PMID:
22811260
15.

Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study.

Nikles CJ, McKinlay L, Mitchell GK, Carmont SA, Senior HE, Waugh MC, Epps A, Schluter PJ, Lloyd OT.

Trials. 2014 Feb 13;15:54. doi: 10.1186/1745-6215-15-54.

16.

Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence.

Beau-Lejdstrom R, Douglas I, Evans SJ, Smeeth L.

BMJ Open. 2016 Jun 13;6(6):e010508. doi: 10.1136/bmjopen-2015-010508.

17.

Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.

Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.

Value Health. 2015 Sep;18(6):824-31. doi: 10.1016/j.jval.2015.06.005. Epub 2015 Aug 20.

18.

Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012.

Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, Schuiling-Veninga CCM, Hoffmann F, Aagaard L, Zito JM.

Eur Neuropsychopharmacol. 2017 May;27(5):484-493. doi: 10.1016/j.euroneuro.2017.03.002. Epub 2017 Mar 20.

PMID:
28336088
19.

The effect of methylphenidate-OROS<sup>®</sup> on the narrative ability of children with attention-deficit hyperactivity disorder.

Rausch TL, Kendall DL, Kover ST, Louw EM, Zsilavecz UL, Van der Merwe A.

S Afr J Commun Disord. 2017 Feb 27;64(1):e1-e12. doi: 10.4102/sajcd.v64i1.180.

20.

Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV.

Sirois PA, Montepiedra G, Kapetanovic S, Williams PL, Pearson DA, Malee K, Garvie PA, Kammerer BL, Nichols SL, Nozyce ML, Mintz M, Mitchell WG, Oleske JM; IMPAACT/PACTG 219C Team.

J Dev Behav Pediatr. 2009 Oct;30(5):403-12.

Supplemental Content

Support Center